AWH - Earnings announcements

Q3 2024 OvaSuiteSM revenue of $2.3 million and volume of 6,001 units Cash utilization for the third quarter was $2.9 million, a decrease of 12% compared to the second quarter of 2024 Full year 2024 cash guidance reconfirmed as $13.0-$14.5 million Conference Call and Webcast scheduled for today at 8:30 am ET AUSTIN, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today reported selected financial results for the third quarter ended September 30, 2024. "OvaWatch® product volume, which we believe is the most import

AUSTIN, Texas, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three and nine months ended September 30, 2024, on Thursday, November 14, 2024. Management will also host a conference call at 8:30 am ET to discuss financial results and provide a corporate update. Details of the call are as follows: Conference Call & Webcast Details:Date:Thursday, November 14, 2024Time:8:30 am ETToll Free:877-545-0320International:973-528-0002Access Code:436613Webcast:R

AUSTIN, Texas, July 31, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months ended June 30, 2024, on Monday, August 12, 2024. Management will also host a conference call at 4:30 p.m. Eastern Time to discuss financial results and provide a corporate update. Details for the call are as follows: Conference Call & Webcast Details:Date: Monday, August 12, 2024Time: 4:30 p.m. ETToll Free:877-407-4018Webcast:Click HERE   A replay of the webcast will also be

AUSTIN, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months ended March 31, 2024, on Wednesday, May 15, 2024. Management will also host a conference call at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. Details for the call are as follows: Conference Call & Webcast Details:Date:Tuesday, May 14, 2024Time:8:30 a.m. Eastern TimeToll Free:877-407-4018Webcast:Click HERECall me™:Click HERE Participants

AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months and year ended December 31, 2023, on Thursday, March 28, 2024. Management will also host a conference call at an updated time of 8:30 am ET to discuss financial results and provide a corporate update. Details for the call are as follows: Conference Call & Webcast Details:Date: Thursday, March 28, 2024Time:  8:30 am ET (NEW TIME)Toll Free: 877-407-4018International:  201-689-

AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months and year ended December 31, 2023 on Thursday, March 28, 2024. Management will also host a conference call at 4:30 pm to discuss financial results and provide a corporate update. Details for the call are as follows: Conference Call & Webcast Details: Date:Thursday, March 28, 2024Time:4:30 pmToll Free:877-407-4018International:201-689-8471Webcast:Click HERECall MeTM:Click HER

AUSTIN, Texas, Oct. 31, 2023 (GLOBE NEWSWIRE) --  Aspira Women's Health Inc. ("Aspira"), a bio-analytical company focused on the development and commercialization of women's health diagnostic tools for gynecologic diseases, today announced that the company will report its financial results for the three months ended September 30, 2023 on Monday, November 13, 2023. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30 p.m. Eastern Time. Details for the call are as follows: Conference call & Webcast Details:Date:Monday, November 13Time:4:30 p.m. Eastern TimeToll Free:1-877-407-4018International:1-201-689-8471Webcast:cl

AUSTIN, Texas, July 31, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira"), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the company will report its financial results for the three months ended June 30, 2023 on Monday, August 14, 2023. Management will host a conference call to discuss financial results and provide a corporate update at 4:30 pm Eastern Time. Details for the call are as follows: Conference call & Webcast Details:Date:Monday, August 14Time:4:30 pm Eastern TimeToll Free:1-877-407-4018International:1-201-689-8471Webcast:Click HERE A replay of the webcast will be available o

First Quarter total product revenue of $2.3 million, an increase of 26% year-over-year First Quarter OvaSuite volume of 6,259 units, an increase of 29% year-over-year First Quarter cash used in operations of $5.7 million, a decrease of 44% year-over-year Conference Call and Webcast scheduled for today 4:30 pm Eastern Time AUSTIN, Texas, May 11, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today reported its financial results for the first quarter ended March 31, 2023. "We saw record growth in both revenues and volume in the first quarter of

Preliminary first quarter 2023 volume was 6,259 tests, an increase of 29% compared to last year, the highest volume quarter in the company's history Management to host its first quarter earnings conference call on Thursday, May 11 at 4:30 pm AUSTIN, Texas, April 27, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira"), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced preliminary first quarter OvaSuite volume and earnings conference call details. Preliminary First Quarter Highlights Preliminary OvaSuite volume increased 29% to 6,259 tests performed during the quarter ended March 31, 2023,

2022 total revenue of $8.2 million, an increase of 20% year-over-year 2022 total OvaSuiteSM volume of 21,423 units, an increase 23% year-over-year Fourth quarter 2022 cash utilization of $7.1 million Conference Call and Webcast scheduled for today at 4:30 pm Eastern Time AUSTIN, Texas, March 22, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today reported its financial results for the fourth quarter and year ended December 31, 2022. "2022 was a year of tremendous transformation as we focused on our three strategic initiatives: growth, innovat

AUSTIN, Texas, March 03, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (NASDAQ:AWH), a bio-analytical based women's health company focused on gynecologic disease, today announced that the company will report its financial results for the year ended December 31, 2022 after the market closes on Wednesday, March 22, 2023. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time. Details for the call are below: Conference Call & Webcast Details Date:Wednesday, March 22Time:4:30pm ETToll Free:1-877-407-4018 International:1-201-689-8471 Conference ID:13736207 Webcast:Click HERE About Aspira Women's Healt

AUSTIN, Texas, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (NASDAQ:AWH), a bioanalytical-based women's health company, today announced that the company will report its financial results for the third quarter ended September 30, 2022 before the market open on Thursday, November 10, 2022. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 8:30 am Eastern Time. Details for the call are below: Conference Call & Webcast:Date:Thursday, November 10Time:8:30 am Eastern TimeToll Free:1-877-407-4018 International:1-201-689-8471 Conference ID:13730748 WebcastClick HERE The webcast will also be available on the Eve

Increased product revenue by 17% to $2.0 million; Grew OVA1plus volume by 19% to 5,411 units Entered into a research agreement with Harvard's Dana Farber Cancer Institute, Brigham & Women's Hospital, and Medical University of Lodz for development of a diagnostic test for endometriosis Reduced cash utilization by $3.9 Million in the Second Quarter 2022 Conference Call and Webcast scheduled for today, August 10th at 8:30 a.m. ET AUSTIN, Texas, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on gynecologic disease, today reported its financial results for the second quarter ended June 30, 2022. "W

AUSTIN, Texas, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira"), a bio-analytical based women's health company focused on gynecologic disease, today announced that the company will report its financial results for the second quarter ended June 30, 2022 before the market open on Wednesday, August 10, 2022. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 8:30am Eastern Time. Details for the call are below: Conference Call & Webcast Details Date:Wednesday, August 10Time:8:30am ETToll Free:1-877-407-4018International:1-201-689-8471Conference ID:13730747Webcast:https://viavid.webcasts.com/starthere.

Product Revenue Increased 30% to $1.8 million; OVA1plus Volume Grew 28% to 4,819 Units New Ordering Physicians in the First Quarter Grew 47% to 603 Year Over Year Board and Leadership appointments announced Conference Call and Webcast scheduled for today, May 11th at 8:30 a.m. ET AUSTIN, Texas, May 11, 2022 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on gynecologic disease, today reported its financial results for the first quarter ended March 31, 2022. "We are pleased to announce our first quarter 2022 results. Strong commercial performance – especially the trend in new ordering physicians - should set

AUSTIN, Texas, April 29, 2022 (GLOBE NEWSWIRE) -- Aspira Women's Health, Inc. (NASDAQ:AWH), a bioanalytical-based women's health company, today announced that the company will report its financial results for the first quarter ended March 31, 2022 before the market open on Wednesday, May 11, 2022. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 8:30am Eastern Time. Details for the call are below: Conference Call & Webcast Details Date:Wednesday, May 11Time:8:30am ETToll Free:1-844-826-3033International:1-412-317-5185Conference ID:10166732 Webcast:https://viavid.webcasts.com/starthere.jsp?ei=1546648&tp_key=889c6ae07f

Total Revenue Increased 46% to $6.8 million; OVA1 Volume Grew 28% to 17,359 Units Exercise of option in the Harvard Dana-Farber Cancer Institute Collaboration Leadership and Board appointments implemented in First Quarter of 2022 Conference Call and Webcast scheduled for today, March 23rd at 8:30 a.m. ET AUSTIN, Texas, March 23, 2022 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on gynecologic disease, today reported its financial results for the fourth quarter and year ended December 31, 2021. "We are pleased to announce our full 2021 results and early 2022 trends. The trend in new ordering physicians as

AUSTIN, Texas, March 15, 2022 (GLOBE NEWSWIRE) -- Aspira Women's Health, Inc. (NASDAQ:AWH), a bioanalytical-based women's health company, today announced that the company will report its financial results for the year ended December 31, 2021 before the market open on Wednesday, March 23, 2022. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 8:30am Eastern Time. Details for the call are below: Conference Call & Webcast Details Date:Wednesday, March 23Time:8:30am ETToll Free:1-877-407-4018 International:1-201-689-8471 Conference ID:13726810 Webcast:https://viavid.webcasts.com/starthere.jsp?ei=1527421&tp_key=e6d813f5a1

Total Revenue Increased 34% to $1.67 million; OVA1 Volume Grew 19% to 4,281 Units Successful Completion of Proof of Concept with Harvard Dana Farber Cancer Institute Collaboration Achieved Over 194 Million Covered Lives for OVA1 Conference Call and Webcast Today at 8:30 a.m. ET AUSTIN, Texas, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on gynecologic disease, today reported its financial results for the third quarter ended September 30, 2021. "We are very pleased with the growth in positive medical policy coverage with the addition of AIM Specialty Health's Clinical Appropriateness Guideli

AUSTIN, Texas, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Aspira Women's Health, Inc. (NASDAQ:AWH), a bioanalytical-based women's health company, today announced that it will report financial results for the third quarter ended September 30, 2021 on Wednesday, November 10, 2021, before the market open, followed by an investor conference call and webcast at 8:30 a.m. Eastern Time. Wednesday, November 10 at 8:30 am ETDomestic:877-407-4018International:201-689-8471Conference ID:13724440Webcast:https://78449.themediaframe.com/dataconf/productusers/vvdb/mediaframe/47156/indexl.html About Aspira Women's Health Inc.Aspira Women's Health Inc. ((formerly known as Vermillion, Inc., NASDAQ:VRML) is transformi

Total Revenue Increased 141% to $1.8 million; OVA1 Volume Grew 85% to 4,553 Accessions New Publication Demonstrates OVA1 Superiority to Standard of Care Expanded Access of OVA1 Through AIM Specialty Health Conference Call and Webcast Today at 4:30 p.m. ET AUSTIN, Texas, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on gynecologic disease, today reported its financial results for the second quarter ended, June 30, 2021. "We are pleased with the volume growth in our products as the economy has somewhat emerged from COVID-19 restriction as well as with the advancement of our preparati

AUSTIN, Texas, July 27, 2021 (GLOBE NEWSWIRE) -- Aspira Women's Health, Inc. (NASDAQ:AWH), a bioanalytical-based women's health company, today announced that it will report financial results for the second quarter ended June 30, 2021 on Thursday, August 12, 2021, after the market close, followed by an investor conference call and webcast at 4:30 p.m. Eastern Time. Thursday, August 12 at 4:30 pm ETDomestic:877-407-4018International:201-689-8471Conference ID:13720544Webcast:http://public.viavid.com/index.php?id=145272 About Aspira Women's Health Inc.Aspira Women's Health Inc. ((formerly known as Vermillion, Inc., NASDAQ:VRML) is transforming women's health with the discovery, development, an